Perrigo
Perrigo is a Top 10 player in the European Consumer Self-Care market and the largest U.S. store brand provider of over the counter and infant formula. We are driven by our mission to Make Lives Better Through Trusted Health and Wellness Solutions, Accessible to All. Dedicated to providing The Best Self-Care for Everyone, we are the people behind the brands you trust. We are Opill®, Compeed®, Solpadeine®, NiQuitin®, ACO®, and many more.
- Est. revenue
- $1B–$1000B
- Total raised
- $4.6B
- Latest round
- Post-IPO Debt
- Employees
- 6,007
Funding & revenue at Perrigo
How well capitalized the business is — useful context before you scope a fractional engagement or negotiate a rate.
Estimated annual revenue
$1B–$1000B
Modeled range, not company-reported
Total capital raised
$4.6B
7 known investors
Latest round
Post-IPO Debt · $1.1B
Sep 2024
Publicly traded
PERRIGO, PRGO
IPO Dec 2013
Status
Acquired
Investors
BofA SecuritiesHSBC SecuritiesHao CapitalJPMorganChaseMorgan Stanley Senior FundingStarboard ValueWells Fargo Securities
Growth signals
How fast Perrigo is adding people, roles, and audience.
Employees
6,007
Reported band 5001-10000
Open roles
3
-1% year over year
LinkedIn followers
114K
+15.3% year over year
Headcount change
- MoM
- -0%
- -2 people
- QoQ
- -0.1%
- -9 people
- 6mo
- -0.2%
- -14 people
- YoY
- -1.3%
- -81 people
- 2yr
- -0.3%
- -21 people
Team composition
Where Perrigo concentrates its people — a read on which function a fractional leader would plug into.
By function
- Operations1,45824%
- Quality Assurance58610%
- Sales4958%
- Information Technology4407%
- Research4187%
- Marketing2364%
- Engineering2334%
- Accounting2324%
By region
- United States3,422
- Michigan, United States2,442
- Grand Rapids Metropolitan Area1,935
- Allegan, MI728
- United Kingdom542
- England, United Kingdom520
Inside Perrigo
What the business focuses on, where it operates, and how employees rate it.
Categories
BiotechnologyManufacturingPharmaceuticalBiotech & PharmaceuticalsPharmaceutical and biotechnology
Markets
NYSE
Offices
- 515 Eastern Ave, Allegan, MI, 49010, US
- , Nazareth, 9810, BE
- , Vienna, AT
- , Paris, FR
- , London, GB
- , Leeds, GB
- , Herrenberg, DE
- , Barcelona, ES
Perrigo in the news
Recent coverage picked up alongside the firmographic refresh.
- Perrigo Co. PLC stock underperforms Thursday when compared to competitors
Sep 2026
- Perrigo (PRGO) Edges Higher to $14.49 While Traders Eye Key Range Boundaries - Momentum Stock Picks
Sep 2026
- Perrigo Settles Antitrust Suits Over Baby Formula Market
Sep 2026
- Zacks Research Has Negative Estimate for Perrigo Q1 Earnings
Aug 2026
- Perrigo to Attend the Barclays Global Consumer Conference
Aug 2026
- Zacks Research Has Bearish Forecast for Perrigo Q3 Earnings
Aug 2026
Jobs
1
Funding, revenue, headcount, and hiring figures are third-party estimates from public sources and are not confirmed by the company. Last refreshed September 25, 2026.
About this page
This company page is automatically generated based on publicly available job postings. Company information is sourced from publicly available data and may not be complete. If you represent Perrigo, you can claim this page to manage and enhance it.